ALX Oncology Holdings Inc (NAS:ALXO)
$ 8.43 -0.09 (-1.06%) Market Cap: 439.20 Mil Enterprise Value: 297.20 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 34/100

ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:50PM GMT
Release Date Price: $86.2 (+0.27%)
Katja Lange
JPMorgan Chase & Co. - Executive Director in healthcare coverage team

Good morning, and thank you, everyone, for joining us today. I'm Kat Lange, a member of the JPMorgan Health Care Investment Banking team. As a quick reminder, after the presentation ends, we will do a quick Q&A session. So if you would like to submit a question, please hit the blue button titled ask a question.

And with that, I would like to hand it over to Jaume Pons, President and CEO of ALX Oncology.

Jaume Pons
ALX Oncology Holdings Inc. - President, CEO & Director

Yes. Thank you, Kat. Good morning. I really appreciate the opportunity to share our data with you today.

After the customary disclaimers in Page #2, let's move to Slide #3. When I started the company in 2015, I was very fortunate to be able to bring with me my dream team of professionals. Today, I want to introduce very specially, Dr. Sophia Randolph, our Chief Medical Officer, and she was a global clinical franchise lead for IBRANCE, the CDK inhibitor of Pfizer, that she developed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot